PIK3CA and breast cancer: For instance, in a cohort of patients with metastatic PIK3CA-mutated breast cancer treated with fulvestrant and palbociclib, a posttreatment decrease in plasma ctDNA PIK3CA levels below the median at cycle 1, day 15, compared with baseline levels was associated with improved PFS (23).